NOS2 and chorioamnionitis: These results could ultimately inform pharmaceutical approaches, such as an iNOS inhibitor or antioxidant, to decrease the rates of preterm labor and sequelae of preterm birth on neonates in the setting of GBS chorioamnionitis.